All questionsSpecific populations: Eliquis (apixaban) in nonvalvular atrial fibrillation9 questions · 3 sourcesSpecific populationsCan Eliquis be used in patients with prosthetic or mechanical heart valves?“Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.” (opens the source at this quote in a new tab)CopyFlagIs Eliquis recommended for patients with antiphospholipid syndrome?“Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome (APS): Direct-acting oral anticoagulants (DOACs), including ELIQUIS, are not recommended for use in patients with triple-positive APS. For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti–beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.” (opens the source at this quote in a new tab)CopyFlagDoes Eliquis need a dose adjustment for kidney impairment in atrial fibrillation?“No dose adjustment is recommended for nonvalvular atrial fibrillation patients unless at least 2 of the following patient characteristics (age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL) are present.” (opens the source at this quote in a new tab)CopyFlag“Renal excretion accounts for about 27% of total clearance” (opens the source at this quote in a new tab)CopyFlag“ELIQUIS is eliminated in both urine and feces. Biliary and direct intestinal excretion contributes to elimination of ELIQUIS in the feces” (opens the source at this quote in a new tab)CopyFlagCan Eliquis be used in patients with atrial fibrillation on dialysis?“Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis In patients with ESRD maintained on intermittent hemodialysis, administration of ELIQUIS at the usually recommended dose will result in concentrations of apixaban and pharmacodynamic activity similar to those observed in the ARISTOTLE study It is not known whether these concentrations will lead to similar stroke reduction and bleeding risk in patients with ESRD on dialysis as were seen in ARISTOTLE” (opens the source at this quote in a new tab)CopyFlag“Hemodialysis in ESRD subjects: Systemic exposure to apixaban administered as a single 5 mg dose in ESRD subjects dosed immediately after the completion of a 4-hour hemodialysis session (postdialysis) is 36% higher when compared to subjects with normal renal function (Figure 3). The systemic exposure to apixaban administered 2 hours prior to a 4-hour hemodialysis session with a dialysate flow rate of 500 mL/min and a blood flow rate in the range of 350 to 500 mL/min is 17% higher compared to those with normal renal function. The dialysis clearance of apixaban is approximately 18 mL/min. The systemic exposure of apixaban is 14% lower on dialysis when compared to not on dialysis.” (opens the source at this quote in a new tab)CopyFlagCan Eliquis be used in patients with liver disease?“MILD hepatic impairment (Child-Pugh class A) No dose adjustment required.2 MODERATE hepatic impairment (Child-Pugh class B) There is limited clinical experience with ELIQUIS in patients with moderate hepatic impairment; dosing recommendation cannot be provided.2 SEVERE hepatic impairment (Child-Pugh class C) ELIQUIS is not recommended.2” (opens the source at this quote in a new tab)CopyFlagIs Eliquis effective and safe in older adults with atrial fibrillation?“Of the total subjects in the ARISTOTLE and AVERROES clinical studies, >69% were 65 years of age and older, and >31% were 75 years of age and older.” (opens the source at this quote in a new tab)CopyFlag“No clinically significant differences in safety or effectiveness were observed when comparing subjects in different age groups.” (opens the source at this quote in a new tab)CopyFlag“Stroke and Systemic Embolism Hazard Ratios by Baseline Characteristics” (opens the source at this quote in a new tab)CopyFlag“n of Events / N of Patients (% per year) Subgroup Apixaban Warfarin Hazard Ratio (95% CI)” (opens the source at this quote in a new tab)CopyFlag“Age <65 (30%) 51 / 2731 (1.0) 44 / 2740 (0.9) 1.16 (0.77, 1.73) ≥65 and <75 (39%) 82 / 3539 (1.3) 112 / 3513 (1.7) 0.72 (0.54, 0.96) ≥75 (31%) 79 / 2850 (1.6) 109 / 2828 (2.2) 0.71 (0.53, 0.95)” (opens the source at this quote in a new tab)CopyFlag“Major Bleeding Hazard Ratios by Baseline Characteristics” (opens the source at this quote in a new tab)CopyFlag“n of Events / N of Patients (% per year) Subgroup Apixaban Warfarin Hazard Ratio (95% CI)” (opens the source at this quote in a new tab)CopyFlag“Age <65 (30%) 56 / 2723 (1.2) 72 / 2732 (1.5) 0.78 (0.55, 1.11) ≥65 and <75 (39%) 120 / 3529 (2.0) 166 / 3501 (2.8) 0.71 (0.56, 0.89) ≥75 (31%) 151 / 2836 (3.3) 224 / 2819 (5.2) 0.64 (0.52, 0.79)” (opens the source at this quote in a new tab)CopyFlagNote: Age of 80 years or older is one of the criteria for the 2.5 mg dose.Can Eliquis be used during pregnancy?“The limited available data on ELIQUIS use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. Treatment may increase the risk of bleeding during pregnancy and delivery, and in the fetus and neonate. Labor or delivery: ELIQUIS use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. Consider use of a shorter acting anticoagulant as delivery approaches.” (opens the source at this quote in a new tab)CopyFlagCan patients breastfeed while taking Eliquis?“Breastfeeding is not recommended during treatment with ELIQUIS.” (opens the source at this quote in a new tab)CopyFlag“There are no data on the presence of apixaban or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Apixaban and/or its metabolites were present in the milk of rats (see Data) . Because human exposure through milk is unknown, breastfeeding is not recommended during treatment with ELIQUIS.” (opens the source at this quote in a new tab)CopyFlagCan Eliquis cause heavy uterine or menstrual bleeding?“Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician. The risk of clinically significant uterine bleeding, potentially requiring gynecological surgical interventions, identified with oral anticoagulants including ELIQUIS should be assessed in these patients and those with abnormal uterine bleeding.” (opens the source at this quote in a new tab)CopyFlag